<DOC>
	<DOCNO>NCT00739063</DOCNO>
	<brief_summary>The goal clinical research study learn TarcevaÂ® ( erlotinib hydrochloride ) help control triple receptor-negative breast cancer . The safety drug also study . Objectives : To assess clinical efficacy , biologic effect safety EGFR inhibitor erlotinib treatment patient 'triple receptor-negative ' metastatic carcinoma breast . Primary endpoint : 1 ) Time progression ( TTP ) Secondary endpoint : 1. clinical benefit rate define complete partial response stable disease 2. overall survival ( OS ) 3. safety profile tolerability erlotinib 4. biologic correlative study</brief_summary>
	<brief_title>Phase II Study Erlotinib , EGFR Inhibitor Metastatic EGFR-positive 'Triple Receptor-negative ' Breast Cancer</brief_title>
	<detailed_description>The Study Drug : Erlotinib hydrochloride design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Screening Tests : Before start treatment study , `` screening test . '' These test help doctor decide eligible take part study . - Blood ( 5 teaspoon ) draw routine test . - If biopsy M. D. Anderson , leftover tissue use confirm breast cancer triple receptor-negative . - If biopsy another location , part biopsy collect tested make sure breast cancer triple receptor-negative . - You image scan , compute tomography ( CT ) bone scan , check status disease . - If tissue available check status disease , breast biopsy . To collect tumor biopsy , affect area numb anesthetic , small amount tissue withdrawn large needle . Study Drug Dose Level : If find eligible take part study , take erlotinib hydrochloride mouth day , every day , breakfast lunch . You take erlotinib hydrochloride 1 hour 2 hour eat . It take time day . Study Visits : Every 8 week , follow test procedure perform : - You physical exam . - Blood ( 5 teaspoon ) draw routine test . - You image scan perform screen check status disease . - You ask side effect may experience . Length Study : You may remain study long benefit . You take study disease get bad intolerable side effect occur . End-of-Study Visit : You end-of-study visit study . The following test procedure perform visit . Blood ( 5 teaspoon ) draw routine test . You image scan repeat check status disease . This investigational study . Erlotinib hydrochloride FDA approve commercially available treatment advance lung cancer advance pancreatic cancer . Its use breast cancer investigational . Up 50 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Patients histologic confirmation metastatic ( stage IV ) 'triple receptornegative ' breast cancer . Tissue must available baseline agree biopsy . The diagnosis 'triple receptornegative ' breast cancer require either primary tumor metastatic deposit show negative estrogen receptor ( ER ) progesterone receptor ( PR ) immunohistochemistry ( IHC ) HER2/neu IHC ( i.e . score 0 1+ ) fluorescent situ hybridization ( FISH ) . 2 . EGFR protein expression gene copy number evaluate stored tissue sample late time . Unstained slide , block , agreement biopsy require study participation . 3 . Patients metastatic breast cancer distant site eligible disease clinically/radiologically measurable 4 . Patients must disease resistant taxanes anthracyclines . There limit number previous therapy metastatic disease . 5 . Patients eligible prior exposure EGFR inhibitor ( e.g.Gefitinib , Erlotinib ) antibody ( e.g . Cetuximab ) . 6 . Availability tissue block and/or fresh/frozen tumor sample eligibility requirement order run EGFR IHC , FISH confirm , need ER , PR HER2/neu status . 7 . Patients may , require , repeat tumor biopsy perform study entry prior begin therapy also early study therapy correlative study . 8 . Patients 'triple receptornegative ' metaplastic breast cancer eligible meet criterion EGFR overexpression . 9 . Patients must sign informed consent indicate aware investigational nature study , keep institutional policy 10 . Patients must tissue block available previous primary tumor surgery biopsy previous biopsy metastatic disease EGFR status assessment correlative study 11 . Patients adequate bone marrow function , define peripheral granulocyte count &gt; /= 1500/mm^3 , platelet count &gt; /= 100000/ mm^3 . Patients must adequate liver function bilirubin within 1.5 time upper limit normal ( ULN ) . Transaminases ( SGPT ) may 5 * ULN alkaline phosphatase may 5 * ULN 12 . Patients adequate renal function ( serum creatinine &lt; /= 1.5 time ULN ) 13 . Negative pregnancy test woman childbearing potential 14 . Women childbearing potential must use reliable appropriate contraceptive method study 15 . Patients performance status 2 good World Health Organization ( W.H.O . ) 1 . Patients uncompensated congestive cardiac failure eligible 2 . Patients myocardial infarction previous 12 month eligible 3 . Patients central nervous system ( CNS ) metastases eligible 4 . Patients organ allograft 5 . Patients serious concurrent infection illness include , limited , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Carcinoma breast</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Triple receptor-negative</keyword>
	<keyword>Triple receptor-negative breast cancer</keyword>
	<keyword>Metastatic triple receptor-negative breast cancer</keyword>
	<keyword>Epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>EGFR-overexpressing</keyword>
	<keyword>GFR inhibitor erlotinib</keyword>
	<keyword>Erlotinib hydrochloride</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
</DOC>